Quadracel vaccine contains diphtheria toxoid, tetanus toxoid, acellular pertussis [pertussis toxoid (PT), filamentous haemagglutinin (FHA), pertactin (PRN), fimbriae types 2 and 3 (FIM)], inactivated poliomyelitis vaccine (IPV) type 1 (Mahoney), type 2 (MEF-1) and type 3 (Saukett)].
Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis.
A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).
March 26, 2015 - Sanofi Pasteur announces FDA approval of Quadracel DTaP-IPV vaccine for children aged 4 to 6
September 4, 2020 - Catholic leaders in the U.S. have welcomed the news that one of the world’s biggest vaccine producers has decided to discontinue a polio vaccine derived from an abortion fetal cell line. Sanofi-Pasteur will instead use an ethical animal cell line in the production of its polio vaccine.
September 21, 2020 - Sanofi Pasteur Ends Use of Aborted Fetal Tissue for Polio Vaccines, a move recently approved by the U.S. Food and Drug Administration.